Zura Bio Limited (ZURA) Stock Forecast
ZURA analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $18.00 average of analyst targets
- Upside to target
- +363.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.22
- 52-week range
- $3.33 – $7.04
ZURA analyst ratings
7 analystsNumber of analysts at each rating.
ZURA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ZURA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.24 | −$0.18 | — | — | 5 |
| Current fiscal year (2026) | −$0.80 | −$0.91 | −$0.62 | −$1.06 | +24.5% | 5 |
| Next fiscal year (2027) | −$0.69 | −$0.99 | −$0.21 | −$0.80 | +13.8% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ZURA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 7 |
ZURA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ZURA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.21 | −$0.21 | −$0.21 | −$0.21 | +7.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.75 | −$0.81 | −$0.81 | −$0.80 | −$0.80 | +6.2% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.64 | −$0.69 | −$0.69 | −$0.69 | −$0.69 | +8.4% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ZURA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ZURA beat in 5 of 12.
What analysts expect from ZURA
7 analysts cover Zura Bio; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.00, 363.9% above the latest close of $3.88. Analysts expect earnings of −$0.80 per share for 2026, +24.5% from a year earlier. For 2027 the average estimate is −$0.69 per share. Zura Bio beat the EPS estimate in 5 of the last 12 quarters.
Related: ZURA income statement, ZURA key metrics, ZURA chart. See the ZURA stock overview for the latest quote and news.
ZURA forecast FAQ
What is Zura Bio's price target?
The average analyst price target for Zura Bio is $18.00, 363.9% above the latest close of $3.88.
Is Zura Bio a buy, hold or sell?
Of 7 analysts covering Zura Bio, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Zura Bio's EPS forecast?
Analysts forecast −$0.80 per share for 2026 (range −$0.91 to −$0.62); for 2027 the estimate is −$0.69.
When does Zura Bio report earnings?
Zura Bio is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.22.
Does Zura Bio usually beat earnings estimates?
Zura Bio reported EPS at or above the analyst estimate in 5 of the last 12 quarters.